CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Ranibizumab 0.5mg +1 moredrug
Likely dose
Ranibizumab 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01926977
NCT01926977Phase 2Completed
CompareCT.gov

Evaluation of Post Injection Inflammation and Pain After Ranibizumab vs Aflibercept Intravitreal Injections

Arshad Khanani·interventional·Posted Aug 21, 2013·Updated Mar 3, 2016

In Brief

A Phase 2 clinical trial evaluating Ranibizumab 0.5mg and Aflibercept 2.0mg for Neovascular Age-Related Macular Degeneration. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-Related Macular Degeneration
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 21, 2013
Enrollment StartSep 1, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.9 years ago

Interventions

Ranibizumab 0.5mgdrug

Patient will receive intravitreal injection of Ranibizumab 0.5mg.

Aflibercept 2.0mgdrug

Patients will receive intravitreal injection of Aflibercept 2.0mg.